Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
Cellectis S.A.
Goethe University
Lanzhou Institute of Biological Products Co., Ltd
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Chicago
Sanofi
Sanofi
M.D. Anderson Cancer Center